These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34525284)

  • 1. BNT162b2 Covid-19 Vaccine in Adolescents. Reply.
    Frenck RW; Dormitzer PR; Gurtman A
    N Engl J Med; 2021 Sep; 385(14):1343. PubMed ID: 34525284
    [No Abstract]   [Full Text] [Related]  

  • 2. BNT162b2 Covid-19 Vaccine in Adolescents.
    Lin CH
    N Engl J Med; 2021 Sep; 385(14):1342-1343. PubMed ID: 34525283
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
    Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
    Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
    Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine.
    Beharier O; Plitman Mayo R; Raz T; Nahum Sacks K; Schreiber L; Suissa-Cohen Y; Chen R; Gomez-Tolub R; Hadar E; Gabbay-Benziv R; Jaffe Moshkovich Y; Biron-Shental T; Shechter-Maor G; Farladansky-Gershnabel S; Yitzhak Sela H; Benyamini-Raischer H; Sela ND; Goldman-Wohl D; Shulman Z; Many A; Barr H; Yagel S; Neeman M; Kovo M
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34014840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
    Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
    Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    Barda N; Dagan N; Balicer RD
    N Engl J Med; 2021 May; 384(20):1970. PubMed ID: 33882227
    [No Abstract]   [Full Text] [Related]  

  • 11. SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine.
    Anderson M; Stec M; Rewane A; Landay A; Cloherty G; Moy J
    JAMA Netw Open; 2021 Aug; 4(8):e2119741. PubMed ID: 34357399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak.
    McEllistrem MC; Clancy CJ; Buehrle DJ; Lucas A; Pruskowski J; Handler SM; Decker BK
    Am J Infect Control; 2021 Oct; 49(10):1237-1241. PubMed ID: 34363871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
    Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
    Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
    Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
    BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
    Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
    JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. Reply.
    Thompson MG; Grant L; Meece J;
    N Engl J Med; 2021 Nov; 385(19):1819-1821. PubMed ID: 34614323
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
    Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
    Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
    Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
    EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.